Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists.
使用 Glucagon-Like Peptide-1 受體激動劑的患者在選擇性食道胃十二指腸鏡檢查後吸入性肺炎的風險。
Cureus 2024-09-06
Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
葡萄糖樣肽受體1激動劑治療與空腹接受麻醉下內視鏡檢查患者胃內容物存在的關聯:一項歷史性的世代研究。
Can J Anaesth 2024-03-15
Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists.
接受胰高血糖素樣肽-1受體激動劑治療時進行上消化道內視鏡檢查的臨床結果和安全性。
Clin Gastroenterol Hepatol 2024-05-01
Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy in Diabetic and Non-Diabetic Patients.
糖尿病和非糖尿病患者上消化道內視鏡檢查中胰高血糖素樣肽-1受體激動劑的影響。
Gastrointest Endosc 2024-05-01
Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes.
糖尿病患者上消化道內視鏡檢查時,GLP-1 受體激動劑不會增加誤吸的風險。
Clin Gastroenterol Hepatol 2024-05-17
The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis.
在接受麻醉或鎮靜的患者中,胰高血糖素樣肽-1受體激動劑的影響:系統性回顧與統合分析。
Perioper Med (Lond) 2024-07-22
Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
在內視鏡程序前是否有必要停止使用胰高血糖素樣肽-1受體激動劑?一項回顧性研究。
World J Gastroenterol 2024-08-01